Hesham Mohamed

发表

Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.

H. Kantarjian, J. Cortes, G. Saglio, 2011 .

Expression of hormone receptors in oropharyngeal squamous cell carcinoma

A. Mäkitie, C. Haglund, J. Hagström, 2018, European Archives of Oto-Rhino-Laryngology.

Toll-like receptor 5 and 7 expression may impact prognosis of HPV-positive oropharyngeal squamous cell carcinoma patients

A. Mäkitie, C. Haglund, J. Hagström, 2017, Cancer Immunology, Immunotherapy.

In HPV-negative oropharyngeal squamous cell carcinoma, elevated toll-like receptor 2 immunoexpression may increase the risk of disease-specific mortality.

A. Mäkitie, C. Haglund, J. Hagström, 2020, Oral oncology.

MMP-7 expression may influence the rate of distant recurrences and disease-specific survival in HPV-positive oropharyngeal squamous cell carcinoma

A. Mäkitie, C. Haglund, J. Hagström, 2018, Virchows Archiv.

Changing trends in the management of the neck in oropharyngeal squamous cell carcinoma

A. Mäkitie, C. Haglund, J. Hagström, 2017, Head & neck.

Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)

R. Paquette, H. Khoury, M. Mauro, 2013 .

Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

K. Norga, D. Faller, G. Vassal, 2020, European journal of cancer.

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.

T. Brümmendorf, H. Kantarjian, J. Cortes, 2014, Blood.

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.

M. Deininger, R. Stone, H. Khoury, 2016, Clinical lymphoma, myeloma & leukemia.

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

S. Mustjoki, J. Cortes, K. Porkka, 2016, Cancer.

3-year follow-up from a randomized phase 3 trial (DASISION) Early response with dasatinib or imatinib in chronic myeloid leukemia:

H. Kantarjian, J. Cortes, C. Chuah, 2014 .

CARDIOVASCULAR (CV)-RELATED HOSPITALIZATION IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN SIMPLICITY, A PROSPECTIVE OBSERVATIONAL STUDY

R. Paquette, M. Mauro, S. Goldberg, 2015 .

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

A. Stamatoullas, P. Fenaux, L. Adès, 2005 .

A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma

R. Rifkin, A. Cartmell, J. Berenson, 2017, American journal of hematology.

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

A. Wei, S. de Botton, Sangmin Lee, 2022, The Lancet. Haematology.

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

H. Colman, B. V. Van Tine, S. Guichard, 2022, Neuro-oncology.

High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study

P. Taimen, I. Leivo, A. Almangush, 2020, Neoplasia.

The expression and prognostic value of stem cell markers Bmi-1, HESC5:3, and HES77 in human papillomavirus–positive and –negative oropharyngeal squamous cell carcinoma

A. Mäkitie, C. Haglund, J. Hagström, 2019, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Expression and Role of E-Cadherin, β-Catenin, and Vimentin in Human Papillomavirus–Positive and Human Papillomavirus–Negative Oropharyngeal Squamous Cell Carcinoma

A. Mäkitie, C. Haglund, J. Hagström, 2020, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Evaluation of prognostic markers for oropharyngeal carcinoma using tissue microarray

Hesham Mohamed, 2019 .

High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the serum are associated with poor prognosis in HPV-negative squamous cell oropharyngeal cancer

A. Mäkitie, C. Haglund, P. Mattila, 2019, Cancer Immunology, Immunotherapy.

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

M. Baccarani, H. Kantarjian, J. Cortes, 2014, Blood.

Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.

J. Esteve, J. Cortes, A. Khwaja, 2021 .

Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

H. Kantarjian, J. Cortes, G. Saglio, 2016, American journal of hematology.

PS1051 FT-2102, AN IDH1 M INHIBITOR, INDUCES MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) TREATED IN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

J. Cortes, G. Schiller, K. Seiter, 2019, HemaSphere.

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

H. Kantarjian, J. Cortes, Sangmin Lee, 2018, Blood.

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

A. Chaudhry, M. Ufkin, H. Prince, 2022, Blood.

Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study

J. Pinilla-Ibarz, Dong-Wook Kim, T. Zyczynski, 2018, Annals of Hematology.

Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a prospective observational study (SIMPLICITY).

J. Cortes, R. Paquette, H. Khoury, 2014 .

Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response

H. Kantarjian, J. Cortes, G. Saglio, 2013 .

The Association Of Dasatinib-Induced Lymphocytosis With Treatment Outcome In Patients With Chronic Myeloid Leukemia (CML)

S. Mustjoki, J. Cortes, K. Porkka, 2013 .

Treponema denticola chymotrypsin-like protease as associated with HPV-negative oropharyngeal squamous cell carcinoma

A. Mäkitie, C. Haglund, J. Hagström, 2018, British Journal of Cancer.

A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

J. Cortes, Sangmin Lee, G. Schiller, 2018 .

Treponema denticola chymotrypsin-like protease as associated with HPV-negative oropharyngeal squamous cell carcinoma

C. Haglund, A. Mäkitie, C. Haglund, 2018, British Journal of Cancer.

CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

S. Lonial, J. Miguel, P. Richardson, 2017 .

CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

S. Lonial, J. Miguel, P. Richardson, 2017 .

Prediction Of Second Generation Tyrosine Kinase Inhibitors Response After Imatinib Failure: The Value Of The Hammersmith Prediction Score

P. Cony-Makhoul, P. Rousselot, L. Roy, 2013 .

K. Norga, D. Faller, G. Vassal, 2020, European journal of cancer.

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

J. Cortes, A. Wei, Sangmin Lee, 2019, Blood.

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

J. Cortes, A. Wei, Sangmin Lee, 2019, Blood.